Yuhan Corporation (KRX:000100)

South Korea · Delayed Price · Currency is KRW

82,300

-2,600 (-3.06%)

Last updated: Aug 31, 2026, 1:41 PM KST

-27.49% (1Y)

Market Cap	6.24T -28.2%
Revenue (ttm)	2.28T +5.4%
Net Income	234.09B +195.3%
EPS	3,139.61 +193.3%
Shares Out	74.76M
PE Ratio	26.66
Forward PE	52.95
Dividend	600.00 (0.72%)
Ex-Dividend Date	Feb 26, 2026

Volume	134,876
Open	83,500
Previous Close	84,900
Day's Range	81,600 - 83,800
52-Week Range	65,000 - 129,200
Beta	0.40
Analysts	Buy
Price Target	120,111.11 (+45.94%)
Earnings Date	Nov 13, 2026

About Yuhan

Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support. The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperl... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1926

Employees 2,087

Stock Exchange Korea Stock Exchange

Ticker Symbol 000100

Full Company Profile

Financial Performance

In 2025, Yuhan's revenue was 2.19 trillion, an increase of 5.75% compared to the previous year's 2.07 trillion. Earnings were 191.09 billion, an increase of 170.33%.

Financial Statements

Analyst Summary

According to 18 analysts, the average rating for 000100 stock is "Buy." The 12-month stock price target is ₩120,111, which is an increase of 45.94% from the latest price.

Price Target

₩120,111

(45.94% upside)

Analyst Consensus: Buy

Stock Forecasts